We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid UTI, Sepsis Tests Uses Digital PCR

By LabMedica International staff writers
Posted on 30 Jan 2020
Sepsis due to antimicrobial resistant pathogens is a major health problem worldwide. More...
The inability to rapidly detect and thus treat bacteria with appropriate agents in the early stages of infections leads to excess morbidity, mortality, and healthcare costs.

Sepsis can be caused by a very low abundance of pathogens in the bloodstream, and most diagnostic technologies require pathogen concentration, a days-long culture step, and pathogen extraction steps that have the potential to reduce sensitivity. Time to diagnosis is also critical in cases of suspected sepsis, as mortality increases 4% for every hour delay until treatment.

Scientists at the University of California, Irvine (Irvine, CA, USA) and their associates have developed a rapid diagnostic platform that integrates a novel one-step blood droplet digital polymerase chain reaction (PCR) assay and a high throughput 3D particle counter system with potential to perform bacterial identification and antibiotic susceptibility profiling directly from whole blood specimens, without requiring culture and sample processing steps.

The team used the cefotaximase-M-9 (CTX-M-9) family extended-spectrum β-lactamases (ESBLs) as a model system, and demonstrated that their technology developed by Velox Biosystems (Irvine, CA, USA) can simultaneously achieve unprecedented high sensitivity (10 CFU per mL) and rapid sample-to-answer assay time (one hour). In head-to-head studies, by contrast, real time PCR and Bio-Rad ddPCR (Bio-Rad, Hercules, CA, USA) only exhibited a limit of detection of 1,000 CFU per mL and 50–100 CFU per mL, respectively.

In the study, the team spiked whole-blood samples with a strain of Escherichia coli containing a synthetic resistance gene and was able to detect bacteria and resistance within one hour. The detection required no culture or sample processing, with a limit of detection of less than 10 colony-forming units per milliliter. The group was also able to demonstrate multiplexing ability for two targets per droplet. The study also detailed strategies to overcome the PCR inhibitory effects common to whole blood, a method to enhance the ability to partition blood into droplets by diluting it, and determined that the ideal fluorophore to get past the autofluorescence of blood was a dye called Quasar 670 from LGC Biosearch Technologies (Teddington, UK).

The team also demonstrated that the technology can be broadly applicable for targeted detection of a wide range of antibiotic resistant genes found in both Gram-positive (vanA, nuc, and mecA) and Gram-negative bacteria, including ESBLs (blaCTX-M-1 and blaCTX-M-2 families) and CREs (blaOXA-48 and blaKPC), as well as bacterial speciation (E. coli and Klebsiella spp.) and pan-bacterial detection, without requiring blood culture or sample processing. The study was first published on December 16, 2019 in the journal Lab on a Chip.

Related Links:
University of California, Irvine
Velox Biosystems
LGC Biosearch Technologies



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Whole Blood Control
Lyphochek Whole Blood Control
New
Multilevel Whole Blood Calibrator Set
6PLUS1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Ear wax could be a possible screening medium for Parkinson’s disease (Photo courtesy of 123RF)

Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules

Current tests for Parkinson’s disease (PD) rely heavily on clinical scales and neuroimaging, which are often subjective, expensive, and ill-suited for routine screening. Since most treatments only slow... Read more

Molecular Diagnostics

view channel
Image: Cord blood proteomics can identify biomarkers of early-onset neonatal sepsis (Photo courtesy of JCI Insight (2025). DOI: 10.1172/jci.insight.193826)

Umbilical Cord Blood Test Can Detect Early Sepsis in Preterm Infants

Diagnosing early onset sepsis (EOS) in preterm infants is particularly difficult due to the lack of specific clinical signs, leading to widespread use of antibiotics while awaiting culture results.... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: NGS can detect one tumor cell among a million healthy cells from a simple blood sample (Photo courtesy of Shutterstock)

New Tool Detects Breast Cancer Relapses Five Years in Advance

Relapse detection in patients with solid tumors—particularly hormone receptor-positive (HR+) breast cancer—remains a major clinical challenge, as many patients initially respond well to treatment but later... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.